THE FUTURE OF FOOD ALLERGIES HAS NEVER LOOKED BRIGHTER

THE FUTURE OF FOOD ALLERGIES HAS NEVER LOOKED BRIGHTER

Pioneering the emerging therapeutic space of oral immunotherapy for food allergies.

Leadership Team

Our team of biotech and pharmaceutical leaders is committed to improving the lives of people living with food allergies. We’re deeply experienced in every aspect of creating and delivering life-improving therapies, from research and development to commercialization to manufacturing.

Andrew Oxtoby

Andrew Oxtoby

President & Chief Executive Officer

Daniel C. Adelman, M.D.

Daniel C. Adelman, M.D.

Head of Research & Development

Nicolas Fouché

Nicolas Fouché

Senior Vice President, Outside U.S. Pharmaceuticals

Alicia Goodman

Alicia Goodman

Senior Vice President, Human Resources

Fabiana Lacerca-Allen

Fabiana Lacerca-Allen

Senior Vice President, Compliance

Cathy Nolan

Cathy Nolan

Senior Vice President, Strategy, Marketing & Innovation

Jim Pepin

Jim Pepin

Senior Vice President and General Counsel

Azfar Qureshi

Azfar Qureshi

Pharma Head of Finance

Narinder Singh

Narinder Singh

Head of Technical Operations

Paul Spence

Paul Spence

Senior Vice President, U.S. Pharmaceuticals

Mohamed Yassine, M.D.

Mohamed Yassine, M.D.

Senior Vice President, Medical Affairs

Andrew Oxtoby has over two decades of experience in the health care and consumer products industries, including extensive global pharmaceutical experience with successful product launches, commercialization, and strategic planning. Mr. Oxtoby joined Aimmune in January 2019 as Chief Commercial Officer and built the commercial organization to prepare for the FDA approval and launch of PALFORZIA in January 2020, transforming Aimmune from a clinical-stage organization to a fully integrated commercial-stage biotechnology company. In October 2020, Mr. Oxtoby was appointed President and Chief Executive Officer.

Before joining Aimmune, Mr. Oxtoby spent 16 years at Eli Lilly and Company where, after having served as Vice President of US Diabetes Sales, he was responsible for Lilly’s US insulin business as Vice President of US Diabetes Connected Care and Insulins, an innovative, patient-focused business unit. While at Lilly, he also spent five years in oncology, including as Vice President of the International Oncology business, was General Manager of Lilly’s Netherlands operation, and held positions of increasing responsibility in marketing and sales. Mr. Oxtoby began his career at Procter & Gamble, where he spent four years in the engineering and manufacturing organizations. Mr. Oxtoby has an MBA from Harvard Business School and a BS in mechanical engineering from Purdue University.

As an allergist and immunologist, Daniel C. Adelman, M.D., has led biotechnology drug development for more than 20 years and has taught and practiced medicine at the University of California, San Francisco, for more than 25 years. Most recently, Dr. Adelman was Chief Medical Officer and Senior Vice President of Development at Alvine Pharmaceuticals Inc., a company focused on autoimmune and inflammatory diseases, particularly celiac disease. He previously held the same positions at Sunesis Pharmaceuticals, Inc. Earlier, Dr. Adelman served in various roles at Pharmacyclics, LLC, including Vice President of Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech, Inc.

Dr. Adelman has published extensively in allergy, clinical immunology and autoimmunity, and oncology. He served on the Research Advisory Board of Food Allergy Research & Education (FARE) for more than five years and on the editorial board of the Journal of Allergy and Clinical Immunology for five years. He now serves on several clinical scientific advisory boards and on the editorial boards of Clinical Immunology and Journal of Clinical Immunology. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned an M.D. from the University of California, Davis.

Nicolas Fouché has 21 years of pharmaceutical and biotechnology experience with the Boston Consulting Group (BCG), AstraZeneca, and most recently Gilead. He joined Aimmune early 2020 as General Manager, France and United Kingdom to prepare for the launch of PALFORZIA; creating country teams and supporting reimbursement efforts; before being promoted in December 2020 to his current position, undertaking the same launch activities across Europe and other geographies in order to bring PALFORZIA to patients worldwide.

Prior to Aimmune, Mr. Fouché’s career spanned positions in Marketing, Sales, Business Development, Strategic Planning, Business Operations and General Management; starting initially as an advisor to pharmaceutical companies at BCG, and then in-market positions in France, the United Kingdom and Japan, and regional roles across EMEA and Central & Eastern Europe; overseeing dozens of launches of Gilead’s Hepatitis C and HIV medicines; and setting up infrastructures for patients to receive life-saving viral treatment. Mr. Fouché is French and holds an MBA from ESSEC (Ecole Supérieure des Sciences Economiques et Commerciales).

Alicia Goodman has more than 20 years of experience in international and strategic human resources planning, talent acquisition and development, and advancing organizational cultures in pharmaceutical and biotech, consumer goods, and telecommunications. Most recently, Ms. Goodman led the human resources function at Millendo Therapeutics, a biotech start-up focused on endocrine diseases. Before that, Ms. Goodman was a principal in a human resources consultancy, during which time she served as ad interim Senior Vice President, Chief People and Culture Officer for Berg IIc, a privately held biotech, as well as ad interim Global Vice President of Human Resources for Alvogen, a privately held pharmaceutical company with commercial operations in 35 countries.

Previously, Ms. Goodman was with Novartis for six years, where she held several human resources roles of increasing responsibility, culminating with the position of Vice President of Human Resources for North America Consumer Health. Ms. Goodman holds an MS in human resources from Central Michigan University and a BA in social science from Michigan State University.

With over 28 years of experience in Compliance and Legal, Ms. Lacerca-Allen has been a leader in developing and implementing global compliance programs within Top Fortune 100 companies. Prior to joining Aimmune, Ms. Lacerca-Allen held several leadership positions at Elan, Mylan, Bristol Myers & Squibb, Microsoft, Merck, AT&T Capital and served as a member of the Board of Directors of Arthrocare, a publicly traded company in the medical device industry. Ms. Lacerca-Allen has extensive experience delineating compliance strategy, leading global teams and negotiating, implementing and executing corporate integrity agreements, deferred prosecution agreements and consent decrees.

She has been recognized by Compliance Week as Top Minds 2019, Hispanic Executive Magazine as Legal Industry Leader and The Guardian as Women in Leadership, Inspiring Leaders. Ms. Lacerca-Allen received her Juris Doctor degree from the Universidad de Buenos Aires and obtained her LLM degree from UCLA where she was the recipient of 1992 UCLA’s tuition waiver based on merit and recognition.

Cathy Nolan has over two decades of experience in the pharmaceutical industry. Prior to joining Aimmune, Ms. Nolan spent 20 years at Eli Lilly and Company, where she was involved in commercial roles in small and large affiliates, global organizations in the US and Europe, and most recently as a Business Unit Leader and Chief Marketing Officer in the UK Hub. Ms. Nolan has deep marketing and commercialization experience and expertise, leading brand building efforts for early phase products in the global organization as well as the commercialization of launch products through to late lifecycle across geographies.

Ms. Nolan joined Aimmune as the Executive Director of Global Marketing and Commercial Capabilities and has been a member of the team since November 2019. She has a Bachelor of Commerce Degree and a Higher Diploma in Marketing Practice from the National University of Ireland, Galway.

Jim Pepin has been practicing law for 20 years, with significant experience in the life sciences and consumer goods industries. Prior to joining Aimmune, Mr. Pepin spent over 10 years with Nestlé HealthCare Nutrition, Inc., where he most recently served as its Vice President & General Counsel. As a member of the senior leadership team, he led the Legal & Compliance function of Nestlé’s U.S. healthcare nutrition business, which markets and sells a diverse portfolio of consumer care nutritional products as well as specialized medical nutrition sold directly to hospitals, long-term care facilities and home healthcare providers.

Prior to joining Nestlé in 2010, he was Acting General Counsel, Corporate Secretary and Compliance Officer of PDI, Inc., a publicly traded pharmaceutical contract sales organization. Mr. Pepin began his legal career as a corporate attorney at Sullivan & Cromwell LLP in London, England and then at King & Spalding LLP in New York, specializing in corporate finance and securities law. Mr. Pepin earned his B.A. in Foreign Affairs from the University of Virginia and a J.D. from the University of Virginia School of Law.

Azfar Qureshi brings 15 years of finance experience in biopharma that includes a demonstrated track record of eight successful product launches in the U.S. and Europe across topicals, small molecules, biologics in a wide array of therapeutic areas including HIV, chronic hepatitis B & C, cystic fibrosis, hematology, oncology, sleep medicine and dermatology.

Prior to joining Aimmune, Mr. Qureshi held finance roles of increasing responsibility in biotech companies including Dermira, Jazz Pharmaceuticals and Gilead Sciences, successfully partnering with executives in support of commercialization efforts including leading and building finance teams.
Mr. Qureshi holds an MBA from University of Pittsburgh and a BS in Mechanical Engineering from Florida International University.

Narinder Singh has over two decades of deep technical, operational, and strategic leadership experience in end-to-end biopharmaceutical clinical development and commercialization, launch, and life cycle management for a variety of biopharmaceuticals. Prior to joining Aimmune, Mr. Singh was Senior Vice President, Pharmaceutical Sciences and Manufacturing at Genocea Biosciences where he was instrumental in technical development and building manufacturing supply chain operations for a personalized neoantigen-based vaccine and an autologous T-cell therapy for solid cancers.

Prior to Genocea, Mr. Singh served at Momenta Pharmaceuticals and at Amgen, Inc. in a variety of leadership roles in drug product and combination device development, commercialization, and manufacturing operations.
Mr. Singh holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from the Indian Institute of Technology in Delhi, India; an M.S. in Chemical Engineering from the University of Houston; and an M.B.A. from the UCLA Anderson School of Management.

Paul Spence has more than 28 years in the healthcare and pharmaceutical market. His highly successful foundation was built upon US and Global roles in marketing, sales, operations, strategy, and commercial leadership sharing his passion for building new teams, launching new models and brands, and leading organizational transformation. Culture and talent development are very important to Paul and central to his approach to leading his teams and partnering cross-functionally. He joined Nestlé Health Science (NHSc) 4 years ago as the Vice President of Medical Nutrition Sales where he transformed his Sales Leadership Team with fast-paced growth initiatives and new GTM models. Most recently he was the Business Executive Officer for NHSc US Pharmaceuticals, leading the integration of Zenpep and Viokace, and developing the NHSc US Pharmaceutical organization and operations across all operating functions in the US and globally.

Previous to NHSc he was with Boehringer-Ingelheim (BI), culminating with the position of Vice President of Sales, South Area. Prior to that he was Executive Director of the Go-to-Market model where he led BI’s national initiative to transform the US medical and commercial customer-facing model to support BI’s long-range forecast, portfolio evolution and marketplace change. Before joining BI, Paul spent 6 years with Sanofi-Aventis where he held several commercial roles to include the build and launch of the Quality Initiatives Organization. His other experience includes marketing, field leadership, and operations roles with Bristol-Myers Squibb and Johnson & Johnson.
Paul earned a BS in finance and accounting from The Pennsylvania State University and an MBA from Villanova University. He also holds several certifications including Six Sigma Green Belt and Loyola University Quality Institute.

Dr. Mohamed Yassine has more than 20 years of Medical Affairs and Clinical Development experience in the biopharmaceutical industry. Prior to joining Aimmune, Dr. Yassine held multiple executive positions, including Head of US Medical Affairs and Head of US Immunology at UCB. He also has served as Executive Director and Therapeutic Area Lead at Amgen. Dr. Yassine has led US and Canadian medical affairs teams while partnering globally and cross functionally in launching more than 10 biologics and pharmaceuticals across multiple specialties with a focus on immunologically based diseases.

He attended McGill University for his Bachelor of Science degree and earned his M.D. at the American University of the Caribbean, St. Bartholomew’s & The Royal London School of Medicine and University of Illinois at Chicago.

Scientific Advisory Board

Many of the world’s most renowned experts in food allergy treatment provide critical peer review and guidance to help optimize our work. Their collective insights help shape our approach to bringing transformative treatments to market that are seamlessly integrated into the clinical practices of allergists, so they can best treat the millions of patients who can benefit.

Kirsten Beyer, M.D., is a Professor in the Department of Pediatric Pneumology and Immunology at University Hospital Charité in Berlin, Germany. Her research experience spans the spectrum of pediatric allergy, with a focus on food allergy. Her interests include food allergy prevention, diagnosis, and treatment. Currently, her group is studying the induction of oral tolerance through oral immunotherapy in food-allergic children and the primary prevention of hen’s egg allergy through early hen’s egg feeding, among other studies.

She is also part of the European Union-funded food allergy project EuroPrevall, studying a European birth cohort of more than 12,000 babies who will be re-evaluated at school age within the EU-funded project iFAAM. Dr. Beyer qualified as an M.D. at the Free University in Berlin and carried out her pediatric training and fellowship at the Humboldt University in Berlin. She was also a visiting scientist at Johns Hopkins University and an Assistant Professor of Pediatrics at Mount Sinai School of Medicine.

A. Wesley Burks, M.D., is Executive Dean for the University of North Carolina School of Medicine as well as the Curnen Distinguished Professor in the Department of Pediatrics. Dr. Burks heads a research team whose work centers on the molecular identification of the allergens in specific foods, a better understanding of the mechanism of adverse food reactions, and the development of treatment for food allergy in preclinical and clinical studies. He and his colleagues have several ongoing clinical studies with different types of mucosal immunotherapy. Dr. Burks is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies.

Dr. Burks earned his medical degree at the University of Arkansas for Medical Sciences, then completed a pediatric residency at the Arkansas Children’s Hospital and a fellowship in allergy and immunology at Duke University Medical Center. Dr. Burks is a past Chair and member of the NIH Hypersensitivity, Autoimmune, and Immune-mediated Diseases study section and was President of the American Academy of Allergy, Asthma and Immunology from 2012 to 2013.

George du Toit, MB, BCh, is a Professor of Paediatric Allergy at King’s College London, Guy’s and St. Thomas’ NHS Foundation Trust, which is home to one of Europe’s largest children’s allergy specialist centers. Dr. du Toit was the lead author of the landmark Learning Early about Peanut Allergy (LEAP) trial and follow-on Persistence of Oral Tolerance to Peanut (LEAP-On) trial, both published in the New England Journal of Medicine. LEAP and LEAP-On showed that feeding peanuts to young children can sharply reduce the risk of their developing peanut allergy and led to new guidelines for the prevention of peanut allergy in many countries, including the US, where new guidelines were published by the National Institute of Allergy and Infectious Diseases.

His research interests concern the prevention of food allergy, urticarial disorders, exercise and allergy, and allergy to medications in childhood. Dr. du Toit earned his Bachelor of Medicine and Bachelor of Surgery degrees from the University of the Witwatersrand in Johannesburg, South Africa, and then specialized in children’s allergy and asthma at the Red Cross Children’s Hospital and the University of Cape Town’s Allergy Diagnostic Clinical Research Unit. Dr. du Toit was Chair of the Pediatric Section of the European Academy of Allergy and Clinical Immunology from 2015 to 2017.

Jonathan Hourihane, M.D., is a Professor of Paediatrics and Child Health at University College Cork in Ireland. His research interests focus on the exploration of the link between skin barrier dysfunction and systemic allergic disorders, threshold doses of food allergens, immunomodulation of established allergic responses, prevention of allergic sensitization, and evaluation of quality of life in food-allergic children. He is co-principal investigator for the BASELINE birth cohort study, which is tracking more than 2000 Irish children from soon after conception over several years to study the effects of intrauterine growth restriction; the incidence and prevalence of food allergy and eczema in early childhood; and the incidence and effects of maternal and infant vitamin D status on growth and health.

He was founding Secretary of the Irish Association of Allergy and Immunology and is founding Chairman of the Irish Food Allergy Network. Dr. Hourihane earned his Bachelor of Medicine, Bachelor of Surgery, and Bachelor of Obstetrics degrees from Dublin University, Trinity College and an M.D. from the University of Southampton.

Stacie M. Jones, M.D., is a Professor of Pediatrics and Chief of Allergy and Immunology at the University of Arkansas for Medical Sciences and Arkansas Children’s Hospital. She is also a researcher at the Arkansas Children’s Research Institute. Her research focuses on both clinical and translational investigation of food allergy and eosinophilic gastrointestinal disorders, as well as on asthma and lung disease.

Dr. Jones is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies. Dr. Jones earned her medical degree at the University of Arkansas for Medical Sciences and completed her pediatrics residency there and at Arkansas Children’s Hospital, followed by a fellowship in pediatric allergy and immunology at Johns Hopkins Hospital.

Wayne G. Shreffler, M.D., PhD, is Chief of Pediatric Allergy and Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and Associate Professor of Pediatrics at Harvard Medical School. At Massachusetts General Hospital, Dr. Shreffler has developed a highly integrated research and clinical program to better understand the pathogenic mechanisms of food allergy and asthma and provide the best current and future care. His lab focuses on the characterization of cellular and humoral immune response to dietary antigens and the mechanisms of allergen-induced Th2 sensitization and oral tolerance. Additionally, Dr. Shreffler is part of the scientific leadership of the multidisciplinary Food Allergy Science Initiative (FASI) at the Broad Institute of the Massachusetts Institute of Technology and Harvard, formed to accelerate food allergy research and development.

He is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies. Dr. Shreffler received his M.D. and PhD degrees from New York University and his pediatrics training at the Albert Einstein College of Medicine, then completed his fellowship in allergy and immunology at the Mount Sinai School of Medicine. He is board-certified in pediatrics and allergy/immunology and is a fellow of the American Academy of Allergy, Asthma and Immunology. He served on the FDA Food Advisory Committee and on the Journal of Allergy and Clinical Immunology Editorial Board.

Brian Vickery, M.D., is an Associate Professor of Pediatrics at Emory University and the founding Director of the Food Allergy Center at Children’s Healthcare of Atlanta. His clinical and research efforts focus on understanding the pathophysiology of food allergies and anaphylaxis, as well as developing new therapies to treat them. Prior to joining the Emory faculty, he led an international Phase 3 randomized clinical trial of peanut oral immunotherapy (OIT), the largest of its kind, as Senior Medical Director at Aimmune Therapeutics. He previously held faculty positions at Duke University School of Medicine and then the University of North Carolina (UNC) School of Medicine, where he was an NIH-funded researcher and the Director of the UNC Food Allergy Initiative.

At UNC, he led a group that was first to show that sustained unresponsiveness (SU), or clinical remission, can occur after peanut OIT and subsequently demonstrated for the first time that the early treatment of peanut-allergic preschool children with OIT is safe and enhances the likelihood of SU. Dr. Vickery obtained his medical degree from the Medical College of Georgia, and he completed his pediatric residency and chief residency at New York-Presbyterian Hospital/Weill Cornell Medical Center and his fellowship training in allergy and clinical immunology at Yale University School of Medicine.